Contact us
Mobile menu not yet fully implemented
The partner searches below are requests that NCP Flanders received from stakeholders abroad.
They have not been widely published and should not be further spread.
These partner search requests are published as received, NCP Flanders does not vouch for the quality of these requests.
If you are a stakeholder based in Flanders and would like to launch a partner search request please contact the NCP advisor responsible for your domain.
The partner searches received by NCP Flanders from stakeholders from abroad are only visible for registered website users.
If you have already an account, you’ll need to login first.
Stakeholder from Flanders but no account? Create your account today!
If you are a stakeholder from abroad and would like to launch a partner search request towards Flemish stakeholders please contact the NCP Flanders advisor responsible for the domain you are interested in.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
